Search Results - BioPharma

37 Results

Sort By:

G9a inhibition decreases stress-induced escalation of alcohol drinking

Technology: Inventors at MUSC have identified that NAc (nucleus accumbens) G9a is required for stress-regulated drinking in both ethanol-dependent and non-dependent animals. Importantly they discovered that treating mice with UNC0642 (an inhibitor of G9a) in a stressinduced ethanol drinking assay (Figure. 1A) showed significant reduction in ethanol...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Ethan Anderson, Christopher Cowan

Keywords(s):

Category(s): BioPharma

Click Chemistry Probes for Specific Targeting of Sialic Acid Tumor Antigens

Technology: Researchers at MUSC have identified methods for selectively modifying linked sialic acid or polysialic acid with bioorthagonal reaction schemes having applications broad applications in drug delivery. This is achieved by exposing a 2,3 linked sialic acid and/or a 2,8 linked polysialic acid to condensing reagents under suitable reaction conditions....

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Richard Drake, Xiaowei (Vivian) Lu

Keywords(s):

Category(s): BioPharma

Recombinant fusion proteins and complement inhibitors targeting P-selectin, and therapeutic and diagnostic application

Technology: Inventors at MUSC have designed fusion proteins to treat inflammatory and other related pathologies by binding p-selectin (PSel) and modulating complement. Although targeting complement has shown great promise in treating numerous pathologies which has also led to the approval of multiple drugs (e.g. eculizumab, Berinert, Cinryze), targeting...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Stephen Tomlinson, Ali Alawieh, Pablo Engel

Keywords(s):

Category(s): BioPharma

CaMKK-β as a target for prevention of noise- and aminoglycoside-induced hearing loss

Compositions and Methods for Attenuation of Hearing Loss Technology: Researchers at MUSC have developed a biopharmaceutical therapy that reduces the expression of specific proteins associated with both noise and chemically induced hearing loss. The invention provides a gene therapy and therapeutic target for prevention of acquired hearing loss. Previous...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Su-Hua Sha

Keywords(s):

Category(s): BioPharma

A new class of alkaloids with potent and selective targeting of pancreatic cancer in vitro

Technology: Inventors from MUSC have identified a class of brominated alkaloid compounds, including aleutianamine, which has potent bioactivity across multiple cancer cell lines in vitro. Extraction and purification of specimens of Latrunculia austini, led to isolation of a potential target mass m/z 398 that resulted from MS/MS molecular ion networking-MoIN...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Mark Hamann, Fred Valeriote

Keywords(s):

Category(s): BioPharma

Monobody R15 targets the nucleotide free state of RAS to block oncogenic signaling and transformation

Technology: Researchers at MUSC and NYU Langone Medical Center have identified a synthetic protein (R15) that selectively binds to the nucleotide-free state of the RAS proto-oncogene (apoRAS) and is the first experimental tool to selectively inhibit the signaling and oncogenic activity of selected oncogenic RAS mutants (Figure 1). The synthetic protein...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): John O'Bryan, Shohei Koide, Akiko Koide

Keywords(s):

Category(s): BioPharma

Inhibition of the Histone Demethylase KDM4B Leads to Activation of KDM1A, Attenuates Bacterial-Induced Pro-Inflammatory Cytokine Release and Reduces Osteoclastogenesis

Technology: Researchers at MUSC have discovered a series of novel small molecules that contain potent immunosuppressive activity and can be used as the new treatment for periodontal disease (PD). PD is caused by bacteria infection in dental plaque, which leads to the inflammation response in the area of gums, periodontal ligament or alveolar bone....

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Patrick Woster, Joy Kirkpatrick (now Gerasco)

Keywords(s):

Category(s): BioPharma

Cyclic Peptide Inhibitors of Lysine-Specific Demethylase 1- Sickle Cell Disease

Technology: Researchers at MUSC have used a ligand-based approach to design and synthesize a series of cyclic peptides that are effective inhibitors of LSD1, and have greater stability to proteolytic degradation than their linear homologues. For example, cyclic peptide 9 inhibits LSD1 in vitro with a Ki value of 385 nM and is significantly more stable...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s):

Keywords(s):

Category(s): BioPharma

Endothelial Progenitor Cell-Derived Exosomes as a Novel Therapeutic in Sepsis

Technology: MUSC researchers have developed a novel therapy to treat sepsis and Acute Respiratory Distress Syndrome (ARDS) using endothelial progenitor cell-derived (EPC) exosomes, which reduced lung and organ injury, inflammation response, and increased survival rate in a mouse model. Data gathered showed that in a sepsis model, IV administration of...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Hongkuan Fan, Andrew Goodwin, Perry Halushka, James Cook, Yue Zhou, Pengfei Li

Keywords(s):

Category(s): BioPharma

M1/Mdivi1 as a novel treatment to reduce immunogenicity in organ transplantation

Technology: Addition of M1 and Mdivi1 drugs in organ preservation solutions can reduce the immunogenicity of the donor organ’s microvascular endothelial cells (ECs), thereby promoting allograft immune tolerance. Inventors at MUSC have found that the use of M1 (a mitochondrial fusion promoter) and Mdivi1 (a mitochondrial fission inhibitor) as a...

Published: 2/5/2023 | Updated: 2/5/2023 | Inventor(s): Satish Nadig, Carl Atkinson, Danh Tran

Keywords(s):

Category(s): BioPharma

1 2 3 4